S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
NASDAQ:RXDX

Prometheus Biosciences Stock Forecast, Price & News

$34.68
-0.14 (-0.40%)
(As of 01/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$32.16
$35.93
50-Day Range
$27.41
$40.12
52-Week Range
$16.11
$40.49
Volume
118,420 shs
Average Volume
219,876 shs
Market Capitalization
$1.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive RXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Prometheus Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Prometheus Biosciences logo

About Prometheus Biosciences

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 2016 and is based in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RXDX
Phone
N/A
Fax
N/A
Employees
26
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.23 million

Profitability

Net Income
$-37.14 million
Net Margins
-2,696.67%
Pretax Margin
-2,719.57%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$1.35 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
11/11/2021
Today
1/25/2022
Next Earnings (Estimated)
2/11/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.14 out of 5 stars

Medical Sector

469th out of 1,416 stocks

Pharmaceutical Preparations Industry

219th out of 684 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Prometheus Biosciences (NASDAQ:RXDX) Frequently Asked Questions

Is Prometheus Biosciences a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prometheus Biosciences in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Prometheus Biosciences stock.
View analyst ratings for Prometheus Biosciences
or view top-rated stocks.

Are investors shorting Prometheus Biosciences?

Prometheus Biosciences saw a increase in short interest in December. As of December 31st, there was short interest totaling 1,580,000 shares, an increase of 45.0% from the December 15th total of 1,090,000 shares. Based on an average daily volume of 256,800 shares, the short-interest ratio is presently 6.2 days. Currently, 6.2% of the company's shares are short sold.
View Prometheus Biosciences' Short Interest
.

When is Prometheus Biosciences' next earnings date?

Prometheus Biosciences is scheduled to release its next quarterly earnings announcement on Friday, February 11th 2022.
View our earnings forecast for Prometheus Biosciences
.

How were Prometheus Biosciences' earnings last quarter?

Prometheus Biosciences, Inc. (NASDAQ:RXDX) released its quarterly earnings data on Thursday, November, 11th. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.59) by $0.11. The biopharmaceutical company had revenue of $1.01 million for the quarter, compared to analyst estimates of $0.38 million. Prometheus Biosciences had a negative trailing twelve-month return on equity of 44.74% and a negative net margin of 2,696.67%.
View Prometheus Biosciences' earnings history
.

What price target have analysts set for RXDX?

7 brokers have issued 1-year target prices for Prometheus Biosciences' shares. Their forecasts range from $30.00 to $50.00. On average, they expect Prometheus Biosciences' stock price to reach $42.86 in the next year. This suggests a possible upside of 23.6% from the stock's current price.
View analysts' price targets for Prometheus Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Prometheus Biosciences' key executives?

Prometheus Biosciences' management team includes the following people:
  • Mr. Mark C. McKenna, Pres, CEO & Director (Age 41, Pay $1.51M)
  • Dr. Keith W. Marshall M.B.A., MBA, Ph.D., CFO & Treasurer (Age 53, Pay $458.22k)
  • Mr. Mark Stenhouse, Chief Operating Officer (Age 54)
  • Dr. Allison Luo M.D., Chief Medical Officer (Age 48, Pay $586.13k)
  • Mr. Gerald T. Proehl, Advisor
  • Dr. Olivier Laurent Ph.D., Chief Technology Officer (Age 49)
  • Dr. Laurens Kruidenier Ph.D., Chief Scientific Officer (Age 51)
  • Ms. Noel Kurdi, VP of Investor Relations & Communications
  • Mr. Timothy K. Andrews Esq., Gen. Counsel & Sec. (Age 42)
  • Ms. Nori Ebersole, Chief People Officer (Age 57)

What other stocks do shareholders of Prometheus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prometheus Biosciences investors own include Cronos Group (CRON), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), (SLS), Freeport-McMoRan (FCX), (KITE) (KITE), La Jolla Pharmaceutical (LJPC), Sorrento Therapeutics (SRNE), TransEnterix (TRXC) and TherapeuticsMD (TXMD).

When did Prometheus Biosciences IPO?

(RXDX) raised $126 million in an initial public offering (IPO) on Friday, March 12th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

What is Prometheus Biosciences' stock symbol?

Prometheus Biosciences trades on the NASDAQ under the ticker symbol "RXDX."

Who are Prometheus Biosciences' major shareholders?

Prometheus Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Strs Ohio (0.02%). Company insiders that own Prometheus Biosciences stock include Joseph C Papa, Mark Stenhouse and Perceptive Advisors Llc.
View institutional ownership trends for Prometheus Biosciences
.

Which institutional investors are buying Prometheus Biosciences stock?

RXDX stock was acquired by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have bought Prometheus Biosciences stock in the last two years include Joseph C Papa, Mark Stenhouse, and Perceptive Advisors Llc.
View insider buying and selling activity for Prometheus Biosciences
or or view top insider-buying stocks.

How do I buy shares of Prometheus Biosciences?

Shares of RXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prometheus Biosciences' stock price today?

One share of RXDX stock can currently be purchased for approximately $34.68.

How much money does Prometheus Biosciences make?

Prometheus Biosciences has a market capitalization of $1.35 billion and generates $1.23 million in revenue each year.

How many employees does Prometheus Biosciences have?

Prometheus Biosciences employs 26 workers across the globe.

What is Prometheus Biosciences' official website?

The official website for Prometheus Biosciences is ignyta.com.

Where are Prometheus Biosciences' headquarters?

Prometheus Biosciences is headquartered at 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States.

How can I contact Prometheus Biosciences?

Prometheus Biosciences' mailing address is 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States. The biopharmaceutical company can be reached via email at [email protected].


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.